- Home
- ABEO
as 11-15-2024 4:00pm EST
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | CLEVELAND |
| Market Cap: | 277.6M | IPO Year: | 1980 |
| Target Price: | $18.00 | AVG Volume (30 days): | 292.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.05 - $9.01 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | 147.52% |
| Revenue Growth (this year): | -94.17% | Revenue Growth (next year): | 7097.06% |
Latest Abeona Therapeutics Inc. News
ABEO Breaking Stock News: Dive into ABEO Ticker-Specific Updates for Smart Investing
GuruFocus.com
3 days ago
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Associated Press Finance
3 days ago
Abeona Therapeutics: Q3 Earnings Snapshot
GlobeNewswire
3 days ago
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
GlobeNewswire
5 days ago
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
GlobeNewswire
13 days ago
Abeona Therapeutics® Announces Participation in November Investor Conferences
GlobeNewswire
16 days ago
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
19 days ago
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
GuruFocus.com
a month ago
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
Compare ABEO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABEO Abeona Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.